CA2772097C - Methods for treating acute acoustic trauma - Google Patents

Methods for treating acute acoustic trauma Download PDF

Info

Publication number
CA2772097C
CA2772097C CA2772097A CA2772097A CA2772097C CA 2772097 C CA2772097 C CA 2772097C CA 2772097 A CA2772097 A CA 2772097A CA 2772097 A CA2772097 A CA 2772097A CA 2772097 C CA2772097 C CA 2772097C
Authority
CA
Canada
Prior art keywords
disulfonyl
tertiary butyl
alpha
acetylcysteine
hearing loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2772097A
Other languages
English (en)
French (fr)
Other versions
CA2772097A1 (en
Inventor
Richard Dana Kopke
Robert A. Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Hough Ear Institute
Original Assignee
Oklahoma Medical Research Foundation
Hough Ear Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Hough Ear Institute filed Critical Oklahoma Medical Research Foundation
Publication of CA2772097A1 publication Critical patent/CA2772097A1/en
Application granted granted Critical
Publication of CA2772097C publication Critical patent/CA2772097C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endoscopes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2772097A 2009-08-24 2010-08-24 Methods for treating acute acoustic trauma Active CA2772097C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27411809P 2009-08-24 2009-08-24
US61/274,118 2009-08-24
PCT/US2010/046420 WO2011028503A1 (en) 2009-08-24 2010-08-24 Methods for treating acute acoustic trauma

Publications (2)

Publication Number Publication Date
CA2772097A1 CA2772097A1 (en) 2011-03-10
CA2772097C true CA2772097C (en) 2019-04-30

Family

ID=43649578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2772097A Active CA2772097C (en) 2009-08-24 2010-08-24 Methods for treating acute acoustic trauma

Country Status (8)

Country Link
US (2) US10555915B2 (https=)
EP (1) EP2470015B1 (https=)
JP (2) JP5762414B2 (https=)
AU (1) AU2010289838C1 (https=)
CA (1) CA2772097C (https=)
ES (1) ES2563777T3 (https=)
IL (1) IL218302A (https=)
WO (1) WO2011028503A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751385B2 (en) 2015-02-20 2020-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
TWI642431B (zh) * 2016-10-28 2018-12-01 西德有機化學藥品股份有限公司 Ｎ－乙醯半胱胺酸用於治療突發性感覺神經性聽力損失的方法
CN110248650A (zh) * 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
KR20190119046A (ko) * 2017-01-19 2019-10-21 오톨로직 파마슈틱스, 인크. N-아세틸시스테인의 제제 및 이의 용도
JP6999896B2 (ja) 2017-09-21 2022-01-19 学校法人慶應義塾 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物
US20210137861A1 (en) * 2018-05-03 2021-05-13 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
AU2019339352B2 (en) * 2018-09-12 2025-05-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
EP4309655A1 (en) * 2022-07-22 2024-01-24 Consejo Superior de Investigaciones Científicas (CSIC) Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6469049B1 (en) 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
SE0001916D0 (sv) 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
WO2004096256A1 (en) 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2005016243A2 (en) 2003-06-09 2005-02-24 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
WO2007119578A1 (ja) 2006-03-29 2007-10-25 Kaneka Corporation 神経系細胞機能改善剤
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
UA97486C2 (ru) 2006-08-29 2012-02-27 Дженентек, Инк. Применение тенектеплазы для лечения острого ишемического инсульта
US20100234402A1 (en) * 2007-05-31 2010-09-16 Gideon Dreyfuss Methods and compositions for treating spinal muscular atrophy
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US20140302322A1 (en) 2011-09-06 2014-10-09 Ricardo Prada Silvy Single wall carbon nanotube purification process and improved single wall carbon nanotubes

Also Published As

Publication number Publication date
AU2010289838A1 (en) 2012-04-19
AU2010289838B2 (en) 2013-11-07
WO2011028503A1 (en) 2011-03-10
US10555915B2 (en) 2020-02-11
JP2013502461A (ja) 2013-01-24
IL218302A (en) 2017-02-28
JP5762414B2 (ja) 2015-08-12
EP2470015B1 (en) 2016-01-13
CA2772097A1 (en) 2011-03-10
US20120172435A1 (en) 2012-07-05
EP2470015A4 (en) 2013-01-09
IL218302A0 (en) 2012-04-30
AU2010289838C1 (en) 2014-03-06
US20170224635A1 (en) 2017-08-10
ES2563777T3 (es) 2016-03-16
JP6038233B2 (ja) 2016-12-07
JP2015172071A (ja) 2015-10-01
EP2470015A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
CA2772097C (en) Methods for treating acute acoustic trauma
JP5236641B2 (ja) 急性音響外傷の治療方法
Kopke et al. Prevention of impulse noise-induced hearing loss with antioxidants
Choi et al. Effectiveness of 4-hydroxy phenyl N-tert-butylnitrone (4-OHPBN) alone and in combination with other antioxidant drugs in the treatment of acute acoustic trauma in chinchilla
Spratley et al. Topical ascorbic acid reduces myringosclerosis in perforated tympanic membranes a study in the rat
EP1471902A1 (en) Methods for treating hearing loss
US8053424B2 (en) Composition and method of treating hearing loss
Pouyatos et al. Oxidative stress pathways in the potentiation of noise-induced hearing loss by acrylonitrile
AU2019204833B2 (en) Treatment of tinnitus using glutamate receptor agonists
Tamir et al. Uniform comparison of several drugs which provide protection from noise induced hearing loss
Pouyatos et al. Lipoic acid and 6-formylpterin reduce potentiation of noise-induced hearing loss by carbon monoxide: Preliminary investigation
US20070105782A1 (en) Protectant Combinations for Reducing Toxicities
US9889156B2 (en) Method for treating noise-induced hearing loss (NIHL)
Humli et al. Protective Effect of Selegiline (R-deprenyl) in Aminoglycoside-Induced Hearing Loss
Choi Preliminary study of the therapeutic effect of a nitrone-based antioxidant drug (HPN-07) on acute acoustic trauma
US9763992B2 (en) Treatment of noise induced hearing loss
JP2004510737A (ja) 薬剤の使用
US20160022699A1 (en) Combinations and methods for treating non age-related hearing impairment in a subject
Fechter et al. Oxidative Stress Pathways in the Potentiation of Noise-Induced Hearing Loss by Acrylonitrile

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250116

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250116

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250825

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250825